Life Sciences

Supported by:

Tuesday 23rd November 2010, One Great George Street - London, 08:40 - 16:35

Life Sciences: Driving Economic Growth and Health Benefit

Overview

The UK life science industry is a world-leading, high-tech industry that will be vital to Britain’s future economy. Working in collaboration with academia and the NHS, the Life Sciences industry develops innovative medicines and medical technologies that bring benefits to patients here and around the world. It is a strong driver of economic growth and provides highly-skilled employment.

It has been over a year and a half since the Office for Life Sciences was established, with an aim to inject new life into the UK life sciences and biotech sector. 'Life Sciences 2010: Delivering the Blueprint' (January 2010) has demonstrated that much has been achieved in this area.

Sir James Dyson’s review (March 2010), commissioned by Prime Minister David Cameron, highlights that to boost small business and life sciences start-ups, we need a cultural change to develop high esteem for science; changes at university level to encourage more young people to choose science; changes in the way that we exploit new knowledge, so that the UK becomes world-class at taking the best new ideas out of universities and onto the market and reforming research and development tax credits with a focus on hi-tech companies, small businesses and new start-ups.

The Business Secretary, Rt Hon Vince Cable MP, outlined in a speech on 3 June 2010 that the government is committed to reducing our deficit by “maximising the economic benefits of our science and research sector…and supporting enterprise.”

Furthermore, as we move into a more challenging financial climate, successful research and innovation in preventing, diagnosing and treating disease will be key to increasing both the quality and productivity of services into the future. The growing partnership between the NHS and the life sciences industry, underpinned by an improved business-to-business relationship, is also of vital importance in ensuring industry can make the maximum contribution to meeting this challenge.

The importance of science and research is recongnised in the government's Comprehensive Spending Review. The government will continue its support for the highest value scientific research, maintaining the science budget in cash terms over the Spending Review period with resource spending of £4.6 billion a year by 2014-15

Agenda

This timely and informative forum will offer stakeholders the opportunity to discuss and examine how the UK’s life sciences can help drive economic growth and patient benefit.

08:30	Registration and Coffee
09:15	Chair’s Welcome Address Professor Robert Slater, Head of School Life Sciences, University of Hertfordshire (CONFIRMED)
09:20	Life Sciences: Delivering our Future Growth The challenges facing our health and social care system The new policy and financial landscape The risks and opportunities for health and social care Approaches to improving care for individuals and saving money in the system Technological solutions to health and social care needs Phil Hope, Former Minister of State for Care Services (CONFIRMED)
09:40	Questions and Answers Session
09:45	Translating Research into Economic and Patient Benefit New funding opportunities for life sciences Fostering opportunities for knowledge transfer and innovation and promoting interaction with the public and other stakeholders on issues of scientific interest in universities, centres and institutes Advancing and disseminating knowledge and technology to improve the quality of life and economic competitiveness in the UK and quality of life Supporting the translation of research into economic impact Encouraging partnerships for health research Dave Tapolczay, Chief Executive, MRC Technology (CONFIRMED)
10:05	Building a Healthy Nation through Business Innovation Converging nanotechnology with the life science industry Supporting business innovation through partnerships, funding and knowledge transfer Opportunities for Life Sciences businesses Innovation and the future of commercial collaboration Future of the RegenMed programme Life science technologies Dr Will Barton, Head of Technology, Technology Strategy Board (CONFIRMED)
10:25	Questions and Answers Session
10:45	Coffee and Networking
11:10	Promoting Excellence in Translational Research NIHR CRN North West Exemplar Programme Promoting excellence in translational research Working in partnership to support high quality and reliable trial delivery Supporting industry to deliver clinical research in the NHS Developing working partnerships with industry Professor Stephen Smye, Director, NIHR Comprehensive Clinical Research Network & Directo, R&D Leeds Teaching Hospitals NHS Trust (CONFIRMED)
11:30	Life Sciences: Working in Partnership to Deliver Economic and Health Benefit Scotland at the forefront of investment in health and the life sciences Role and remit of the Scottish Universities Life Science Alliance Building a sustainable Life Sciences skills base Commercialising the output of life sciences research base Building a commercialisation culture in academia Examples of successful academic entrepreneurs Improving the strategic relationship between NHS and academia Dr Robert Ford, Business Development Manager, Research and Innovation Services, University of Dundee & Chair of Knowledge Exchange Committee, Scottish Universities Life Science Alliance (CONFIRMED)
11:50	Biotech Reinvented: Where do you go from here? Challenges and opportunities facing the pharmaceuticals and lifesciences industry The role of the Biotech industry Convergence of Biotech and Pharma New collaborative business models to accelerate and facilitates the discovery and development process coordinating the biopharma industry, research institutes, academic medical centres and healthcare players Jo Pisani, Partner PwC, UK Pharma & Lifesciences Strategy Leader, PricewaterhouseCooper (CONFIRMED)
12:10	Questions and Answers Session
12:30	Lunch and Networking
13:30	Afternoon Keynote: Supporting NHS as an Innovation Champion NICE appraisal process NICE methodologies Determining cost-effectiveness and value of innovation Strengthening engagement and dialogue with life science industry to improve patient benefit Industry engaging with Appraisal Committees Securing a successful future for the life sciences industries Response to the Kennedy Report Future of the Innovation Pass Sir Michael Rawlins, Chairman, National Institute of Health & Clinical Excellence (NICE) (CONFIRMED)
13:50	Supporting Pre-Commercial Procurement in the NHS Identifying commercial opportunities in the NHS Transforming good ideas into workable solutions for the NHS Speeding up the time it takes for innovative solutions to get from the design to implementation stages Creating a support structure for innovation Brian Winn, Head, NHS National Innovation Centre (CONFIRMED)
14:10	Opportunities for Life Sciences Businesses Funding opportunities for life sciences Opportunities for international collaboration Collaborative research in the health theme Optimizing the delivery of healthcare Stéphane Hogan, Head of Unit - Horizontal Aspects & Coordination, European Commission (CONFIRMED)
14:30	Sponsor: The New Health and Biopharma's Changing Business Model The Need For Change Clinical-Commercial Convergence New Commercial Models The Challenge for Quintiles Phil Krzyzek, Business Development Director for Health Management Solutions, Quintiles UK (CONFIRMED)
14:50	Questions and Answers Session
15:00	Coffee and Networking
15:20	Research and Innovation in Life Sciences: The Industry Perspective Building a more integrated life sciences industry Access to finance and stimulating investment How can we speed up the time it takes for innovative solutions to get from the design to implementation stages How can we improve the strategic relationship between the NHS and industry through joint working projects Enhancing collaboration in life sciences Supporting the commercial success of the bioscience industry by focusing on emerging enterprise Dr Louise Leong, Head of R&D, Association of the British Pharmaceutical Industry (CONFIRMED)
15:40	Attracting Inward Investment in Life Sciences: Selling our Strengths Abroad Selling our strengths abroad and attracting inward investment Renewed focus on high priority sectors and markets UK life sciences sector as a world leader in innovation Creating an environment where the discovery of new medicines, procedures and technologies can prosper Promoting excellence in British healthcare manufacture, services, technology and innovation Boosting life sciences start-ups and attracting inward investment Internal trade opportunities Exploiting the UK’s position as a world leader in health informatics Marketing UK life sciences Jon Mowles, UK Trade & Investment Sector Champion, UK Trade & Investment (CONFIRMED)
16:00	Closing Keynote: A Modernised Healthcare Science Workforce Professor Sue Hill, Chief Scientific Officer, Department of Health (CONFIRMED)
16:20	Questions and Answers Session
16:35	Chair's Closing Remarks and Close

*programme subject to change without notice

Sponsor:

Quintiles

Exhibitor:

Audience

Delegates attending this forum will include heads of innovation programmes, directors of enterprise, directors of infection control, knowledge transfer managers, research directors, heads of new business, medical directors, section heads of microbiologists, heads of clinical care, quality improvement directors, education governance managers, heads of medicine management and commissioning, pharmacy services managers, clinical microbiologists, and will be drawn from central government, health authorities, research councils, academia, funding councils, third sector and the private sector.